Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

The same mRNA technology that made the COVID-19 vaccine possible will soon be used in flu vaccines for older Americans. The FDA has approved a new shot from Moderna called mFlusiva for adults aged 50 to 64. The company is also seeking full approval for adults 65 and older....

14,936 Aufrufe • vor 1 Monat •via X (Twitter)

10 Kommentare

Profilbild von Reactor99
Reactor99vor 1 Monat

However the trials showed a higher rate of side effects compared to the current flu vax

Profilbild von Raven Cain 🐦‍⬛ 🏳️‍🌈🏳️‍⚧️
Raven Cain 🐦‍⬛ 🏳️‍🌈🏳️‍⚧️vor 1 Monat

Bracing for the inevitable MAGA crashout.

Profilbild von UBIK
UBIKvor 1 Monat

Pro tip - It's a rule of thumb among IT pros that one should never be among the first to install a Windows update, as experience shows they can be buggy. The same principle applies in CAPITAL LETTERS to substances injected into your body. Let someone else be the guinea pigs.

Profilbild von Frank the Tank
Frank the Tankvor 1 Monat

Is it safe and effective?

Profilbild von ElizabethFairbank
ElizabethFairbankvor 1 Monat

There are already many posts, including from Marjorie Taylor Greene--who is NOT a medical expert, claiming that the new vaccine is dangerous. So sick of this bullshit. LOOK IT UP FOR YOURSELVES, PEOPLE! Do not trust politicians and COVID deniers with your health!

Profilbild von Neil
Neilvor 1 Monat

This won't freak MAGA out at ALL...

Profilbild von marty
martyvor 1 Monat

No $$ in healthy people.

Profilbild von Anton S
Anton Svor 1 Monat

MAGAtards need not vaccinate... go suffer together

Profilbild von Blonde In The Burbs
Blonde In The Burbsvor 1 Monat

@AlexBerenson no reference to the concerns you raised in yesterday's substack. Big pharma owns the media, too.

Profilbild von Tc
Tcvor 1 Monat

😂 The FDA will approve anything for the right price. For example, COVID treatments they KNEW didn't work.

Ähnliche Videos

The FDA has approved Moderna's mRNA flu vaccine, the first flu shot using mRNA technology to reach the US market. The approval comes months after the same agency refused to even file Moderna's original application. Vinay Prasad, who took over the FDA's biologics division after Peter Marks, rejected the initial application in writing, citing the trial as not adequate and well controlled. His internal memo to FDA staff, later leaked to the Washington Post, called the annual flu vaccine framework an evidence-based catastrophe of low quality evidence, poor surrogate assays, and uncertain effectiveness measured with poor methods. Twelve former FDA chiefs responded by blasting his move to tighten vaccine standards in the New England Journal of Medicine. Prasad has since left the agency. ICAN submitted a letter to the FDA's independent VRBPAC committee before the vote laying out the problems: the vaccine was compared not against placebo but against a GSK product that Prasad himself called not best in class, the absolute influenza risk reduction was only 0.8% while the adverse reaction profile ran at 6.4%, the trial used a single season of data, and Part A of the trial produced more patient deaths than the comparator flu shot. The committee approved it anyway. Del Bigtree and Jefferey Jaxen walk through why this matters beyond the flu shot itself: mRNA technology, justified under COVID emergency conditions, is now entering the routine recommended schedule through a non-emergency approval, and will be the first mRNA product included in the vaccine injury compensation table. The flu shot is currently approved for adults 50 and older, fast-tracked for 65 and older.

The HighWire

19,164 Aufrufe • vor 1 Monat